Latham & Watkins Advises on Ginkgo Bioworks Holdings, Inc.’s US$100 Million At-the-Market Equity Offering Program

Ginkgo Bioworks Holdings, Inc. (NYSE: DNA), the biotech company building a platform to enable customers to program cells as easily as we can program computers, has announced a US$100 million At-The-Market (ATM) equity offering program with Allen & Company LLC as sales agent.

Latham & Watkins LLP represented the sales agent in the transaction with a Capital Markets team led by Los Angeles partners Steve Stokdyk and Brent Epstein, with associates Eric Finkelberg and Steve Hess.